share_log

HOOKIPA Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%), etc.

HOOKIPA Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%), etc.

HOOKIPA Pharma | SC 13G：超過5%持股股東披露文件-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%)等
美股SEC公告 ·  07/09 06:53
牛牛AI助理已提取核心訊息
On June 1, 2023, a Schedule 13G was filed with the United States Securities and Exchange Commission by several entities and an individual, indicating a change in ownership of shares in HOOKIPA Pharma Inc. The filing revealed that Invus Public Equities, L.P., along with its advisors and related entities, including Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, and Mr. Amaury Wittouck, collectively hold 5,666,410 shares of common stock in HOOKIPA Pharma. This represents 5.9% of the company's class as of the filing date. Previously, on June 1, 2023, the percentage of class owned was reported as 7.3%. The shares are reported to be held with sole voting and dispositive power by each reporting person, with no shared power reported. The filing includes a certification that the shares were not acquired for the purpose of changing or influencing the control of HOOKIPA Pharma Inc. and were not held in connection with any transaction having such purpose or effect.
On June 1, 2023, a Schedule 13G was filed with the United States Securities and Exchange Commission by several entities and an individual, indicating a change in ownership of shares in HOOKIPA Pharma Inc. The filing revealed that Invus Public Equities, L.P., along with its advisors and related entities, including Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, and Mr. Amaury Wittouck, collectively hold 5,666,410 shares of common stock in HOOKIPA Pharma. This represents 5.9% of the company's class as of the filing date. Previously, on June 1, 2023, the percentage of class owned was reported as 7.3%. The shares are reported to be held with sole voting and dispositive power by each reporting person, with no shared power reported. The filing includes a certification that the shares were not acquired for the purpose of changing or influencing the control of HOOKIPA Pharma Inc. and were not held in connection with any transaction having such purpose or effect.
2023年6月1日，幾家公司和個人向美國證券交易所提交了13G日程表，表明HOOKIPA Pharma Inc.股票的持有人發生了變化。提交的文件揭示，包括Invus Public Equities、其顧問和相關實體、Artal International S.C.A.、Artal International Management S.A.、Artal Group S.A.、Westend S.A.、Stichting Administratiekantoor Westend和Amaury Wittouck先生在內的衆多機構共持有HOOKIPA Pharma普通股5,666,410股。這代表着...展開全部
2023年6月1日，幾家公司和個人向美國證券交易所提交了13G日程表，表明HOOKIPA Pharma Inc.股票的持有人發生了變化。提交的文件揭示，包括Invus Public Equities、其顧問和相關實體、Artal International S.C.A.、Artal International Management S.A.、Artal Group S.A.、Westend S.A.、Stichting Administratiekantoor Westend和Amaury Wittouck先生在內的衆多機構共持有HOOKIPA Pharma普通股5,666,410股。這代表着該公司截至提交日期的5.9%的所有類別。此前，2023年6月1日，所報告的所持類別比例爲7.3%。據報告，每個報告人都擁有所報告的股份的唯一投票和決策權，沒有共同的權力。提交的文件包括一份證明，表明這些股份不是爲了改變或影響HOOKIPA Pharma Inc.的控制權而收購的，也不是爲了和任何有這樣的目的或效果的交易而持有的。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。